Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name
Ng Cheng Han, Huang Daniel Q., Nguyen Mindie H.,
소속 상세정보
( Ng Cheng Han )
National University of Singapore Yong Loo Lin School of Medicine
( Huang Daniel Q. )
National University of Singapore Yong Loo Lin School of Medicine
( Nguyen Mindie H. )
Stanford University Medical Center Division of Gastroenterology and Hepatology
Abstract
Nonalcoholic fatty liver disease (NAFLD) affects about a third of the world’s adult population and is a major public health concern. NAFLD is defined by the presence of hepatic steatosis and the absence of other causes of liver disease. As NAFLD is closely associated with the presence of the metabolic syndrome, several experts have called for a change in nomenclature from NAFLD to metabolic-associated fatty liver disease (MAFLD) to better reflect the underlying pathophysiology of NAFLD as a metabolically driven disease and shift to a “positive” diagnostic criteria rather than one of exclusion. Recent studies have suggested that the global prevalence of MAFLD is higher than that of NAFLD, and patients with MAFLD have more metabolic comorbidities compared to those with NAFLD. Emerging data also suggest that all-cause and cardiovascular mortality may be higher in MAFLD compared with NAFLD. In this synopsis, we discuss differences in clinical features, prevalence and clinical outcomes between NAFLD and MAFLD. In addition, we highlight the advantages and disadvantages of a name change from NAFLD to MAFLD from the perspective of the scientific community, care providers and patients.
키워드
Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Liver, Nonalcoholic fatty
원문 및 링크아웃 정보
등재저널 정보
SCI(E)
MEDLINE
KCI
KoreaMed
KAMS